Guidelines for treatment in severe chronic obstructive pulmonary disease with hyperinflation now include endobronchial lung volume reduction. Since December 2018, 2 valve systems have been Food and Drug Administration (FDA) approved, which has generated widespread interest in this new therapy for chronic obstructive pulmonary disease treatment. Although the technical placement of the endobronchial valves is relatively straightforward, this paper focuses on the multidisciplinary approach to identification, evaluation, and follow-up in addition to procedural techniques for endoscopic lung volume reduction implementation.
- endobronchial lung volume reduction
- lung valve
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine